NASDAQ:ORIC Oric Pharmaceuticals Q3 2024 Earnings Report $10.43 -0.22 (-2.07%) Closing price 04:00 PM EasternExtended Trading$10.58 +0.15 (+1.44%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Oric Pharmaceuticals EPS ResultsActual EPS-$0.49Consensus EPS -$0.48Beat/MissMissed by -$0.01One Year Ago EPSN/AOric Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOric Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time4:00PM ETUpcoming EarningsOric Pharmaceuticals' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Sunday, August 10, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Oric Pharmaceuticals Earnings HeadlinesORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5 at 11:45 AM | morningstar.comMORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 8 at 2:00 AM | Brownstone Research (Ad)Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJuly 3, 2025 | theglobeandmail.comOric Pharmaceuticals Inc. Advanced Charts | ORIC | Barron'sJune 28, 2025 | barrons.comOric Pharmaceuticals Shows Market Leadership With Jump To 93 RS RatingJune 25, 2025 | msn.comSee More Oric Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oric Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oric Pharmaceuticals and other key companies, straight to your email. Email Address About Oric PharmaceuticalsOric Pharmaceuticals (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing oral targeted therapies designed to overcome fundamental cancer resistance mechanisms. The company’s research strategy centers on identifying and inhibiting key signaling pathways and microenvironmental factors that drive tumor survival and proliferation. By focusing on oral small molecules, Oric aims to provide patients with convenient, potentially more tolerable treatment options compared with intravenous regimens. The company’s lead programs include ORIC-101, a selective oral glucocorticoid receptor antagonist in Phase 1/2 clinical studies for solid tumors, and ORIC-944, a potent inhibitor of the cell-cycle checkpoint kinase Wee1 currently under evaluation in advanced cancer indications. In addition to its clinical-stage assets, Oric maintains a preclinical pipeline targeting mechanisms such as fibroblast growth factor receptor (FGFR) aberrations and other cell-cycle dependencies. Oric’s early-stage studies are being conducted across multiple sites in the United States and Europe, often in collaboration with leading academic cancer centers. Founded in 2016 by a team led by Dr. Roger M. Perlmutter—a veteran pharmaceutical executive and former president of Merck Research Laboratories—and Dr. Jay Bradner of Harvard’s Novartis Institute for Biomedical Research, Oric has built a leadership team with deep expertise in oncology drug development. The company is led by President and Chief Executive Officer Todd Braunstein, who brings extensive experience in global biopharmaceutical strategy and operations. Its board and scientific advisory group include seasoned leaders from both industry and academia. Oric Pharmaceuticals serves patients and healthcare providers worldwide, with a mission to deliver next-generation therapies that address the adaptive resistance often seen with current cancer treatments. By combining insights from cancer biology with a focus on oral delivery, Oric seeks to advance a portfolio of best-in-class candidates that can meaningfully improve outcomes for patients facing challenging solid tumor diagnoses.Written by Jeffrey Neal JohnsonView Oric Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
